Christopher Venner

6PUBLICATIONS
46CO-AUTHORS
Gene and molecular therapyNanomedicinePredictive and prognostic markersPharmacogenomicsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Mar 11, 2026
Debulking Chemotherapy Can Overcome Primary Resistance to Teclistamab in Relapsed/Refractory Multiple Myeloma.

Rintu Sharma, Andree-Anne Pelland, Katherine Lajkosz

|Dec 29, 2023
Frontline therapy with bendamustine rituximab (BR) and rituximab cyclophosphamide vincristine prednisone (RCVP) confers similar long-term outcomes in patients with treatment naïve Waldenström macroglobulinemia in a real-world setting: a population-based analysis.

Jowon Laura Kim, Alina S Gerrie, Kerry Joane Savage

|Aug 13, 2023
Outcome of carfilzomib/pomalidomide-based regimens after daratumumab-based treatment in relapsed multiple myeloma: A Canadian Myeloma Research Group Database analysis.

Richard LeBlanc, Hira Mian, Donna Reece

|Mar 16, 2022
Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the ANDROMEDA study.

Vaishali Sanchorawala, Giovanni Palladini, Monique C Minnema

|Mar 02, 2021
Weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed/refractory multiple myeloma: Final results from the MCRN-003/MYX.1 single arm phase II trial.

Christopher P Venner, Richard LeBlanc, Irwindeep Sandhu

Pageof 1

Frequent Collaborators

2 joint publications

Esther Masih-Khan

2 joint publications

Donna Reece

1 joint publications

Rintu Sharma

1 joint publications

Andree-Anne Pelland